A Study of LY3209590 in Participants With Type 2 Diabetes

Inclusion criteria

• Participants with Type 2 Diabetes Mellitus (T2DM) for at least 1 year
• Have a glycated hemoglobin (HbA1c) greater than or equal to (≥) 7.0 percent (%) to less than or equal to (≤) 10.5% at screening
• Have had no episodes of severe hypoglycemia in the past 6 months
• Are on stable basal insulin (neutral protamine Hagedorn insulin suspension [NPH] insulin, insulin glargine [U100 or U300], or insulin detemir) with or without metformin, dipeptidyl peptidase IV (DPP-IV) inhibitors, sulfonylureas, and sodium-glucose co-transporter 2 (SGLT-2) inhibitors, at a stable dose for at least 3 months before screening

Exclusion criteria

• Have significant lipohypertrophy in the target abdominal injection
• Have a history of renal impairment
• Have a history of deep vein thrombosis of the leg or repeated episodes of deep leg vein thrombosis in first-degree relatives (parents, siblings, or children)
• Have proliferative retinopathy or maculopathy and/or severe neuropathy
• Any significant changes in insulin regimen and/or unstable blood glucose control within the past 3 months prior to screening
• Require daily insulin treatment less than (<) 0.15 unit/kilogram (U/kg) per body weight
• Are treated with a continuous subcutaneous insulin infusion (CSII) pump
• Currently receiving degludec insulin therapy, or have been treated with degludec within the past 90 days